Skip to main content
Our Medicines
Contact Us
Careers
United Kingdom
Close Icon
Americas
Argentina
Spanish
Brazil
Portuguese
Canada
English
/
French
Chile
Spanish
Colombia
Spanish
Mexico
Spanish
Peru
Spanish
United States
English
Asia Pacific
Australia
English
China
Simplified Chinese
India
English
Japan
Japanese
Korea
Korean
New Zealand
English
Singapore
English
Taiwan
Traditional Chinese
Thailand
English
/
Thai
Europe
Austria
German
Belgium
English
/
Dutch
/
French
Czech Republic
Czech
Denmark
Norwegian
Finland
Finnish
France
French
Germany
German
Greece
Greek
Hungary
Hungarian
Ireland
English
Italy
Italian
Luxembourg
English
Netherlands
English
/
Dutch
Norway
Norwegian
Poland
Poland
Portugal
Portuguese
Romania
Romanian
Spain
Spanish
Sweden
Swedish
Switzerland
German
/
French
United Kingdom
English
Middle East
Israel
Hebrew
Saudi Arabia
Arabic
/
English
Turkey
Turkish
United Arab Emirates
Arabic
/
English
Other
Other Markets
Distributor Markets
Previous Page Icon
Previous Page Icon
Our Medicines
Patients & Caregivers
Healthcare Providers
Medical education resources
Researchers & Partners
Our Therapy Areas
Our Stories
People
Next Page Icon
The Path to Progress: Research and Development Spotlight
Forging the Future with the University of Birmingham: The power of industry and academic PhD partnerships
The Path to Progress: Clinical Trials Spotlight
The Path to Progress: Regulatory Affairs and Medical Affairs Spotlight
The Path to Progress: Market Access Spotlight
The Path to Progress: Sales and Marketing Spotlight
Science
News & Perspectives
Next Page Icon
Our UK facility in the North West exemplifies sustainability innovation
Putting Moreton on the map: How our R&D site in the North-West of England is harnessing local investment to become a global hub for innovation
Pioneering Solutions for a Greener Future
Celebrating 10 years of C2C4C
Driving a transformative approach to understanding menopause in the workplace
Squaring the impossible circle: Looking to a future of improved cancer patient experience and efficient care
Cancer Equals: UK wide research highlights differences in cancer care
Bristol Myers Squibb expands health equity grant initiatives to improve health outcomes
Guy Oliver appointed as General Manager for Bristol Myers Squibb UK and Ireland
A top 10 placing for BMS in the UK’s Best Workplaces 2024 List
Lung cancer experts address unwarranted variation in diagnosis and treatment
Bristol Myers Squibb earns coveted spot on this year's UK’s Best Workplaces in BioPharma list
Behind the bio: Meet Karen Costello
About Us
Our Mission
Our Principles
Responsibility
Next Page Icon
Partnering
Transparency
Grants, Giving & Corporate Sponsorship Support
UK Tax Strategy
Inclusion & Diversity
Donations & Grants
Global Patient Week
Global Patient Week 2023
Sustainability
Doing Business with Us as a Supplier
Contact Us
Our Site at Chester
Our Site at Moreton
Our Site at Uxbridge
Life Sciences 2030
More than Guts: Inflammatory bowel disease podcast
Transforming cancer outcomes in the UK: clearing the backlog, improving capacity and building services for tomorrow
People and Business Resource Groups
The Path to Progress
More than Inherited Cardiac Conditions (ICCs): BMS launches report at parliamentary summit for improving outcomes in ICCs
Search
Search
Search
Our Stories
People
Science
News & Perspectives
Catch up on our latest activities and read our views on what is happening in the UK life sciences industry, how it impacts our work and our patients.
01/11/24
Behind the bio: Meet Karen Costello, the new General Manager for our commercial affiliate in Ireland
18/09/24
Bristol Myers Squibb earns coveted spot on this year's UK’s Best Workplaces in BioPharma list
04/07/24
Lung cancer experts address unwarranted variation in diagnosis and treatment
22/04/24
Bristol Myers Squibb expands health equity grant initiatives to improve health outcomes
22/04/24
Guy Oliver appointed as General Manager for Bristol Myers Squibb UK and Ireland
22/04/24
A top 10 placing for BMS in the UK’s Best Workplaces 2024 List
Load More
NO-GB-2400280
November 2024
